1. Hanno P, Levin RM, Monson FC, Teuscher C, Zhou ZZ, Ruggieri M, et al. Diagnosis of interstitial cystitis. J Urol 1990;143:278-281. PMID:
2299717.
2. Hanno P, Keay S, Moldwin R, Van Ophoven A. International Consultation on IC - Rome, September 2004/Forging an International Consensus: progress in painful bladder syndrome/interstitial cystitis. Report and abstracts. Int Urogynecol J Pelvic Floor Dysfunct 2005;16(Suppl 1):S2-S34. PMID:
15883858.
3. Parsons CL, Lilly JD, Stein P. Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis). J Urol 1991;145:732-735. PMID:
2005689.
4. Sant GR, Hanno PM. Interstitial cystitis: current issues and controversies in diagnosis. Urology 2001;57(6 Suppl 1):82-88. PMID:
11378054.
5. Nordling J, Anjum FH, Bade JJ, Bouchelouche K, Bouchelouche P, Cervigni M, et al. Primary evaluation of patients suspected of having interstitial cystitis (IC). Eur Urol 2004;45:662-669. PMID:
15082211.
6. Bogart LM, Berry SH, Clemens JQ. Symptoms of interstitial cystitis, painful bladder syndrome and similar diseases in women: a systematic review. J Urol 2007;177:450-456. PMID:
17222607.
7. Tomaszewski JE, Landis JR, Russack V, Williams TM, Wang LP, Hardy C, et al. Biopsy features are associated with primary symptoms in interstitial cystitis: results from the interstitial cystitis database study. Urology 2001;57(6 Suppl 1):67-81. PMID:
11378053.
8. Phatak S, Foster HE Jr. The management of interstitial cystitis: an update. Nat Clin Pract Urol 2006;3:45-53. PMID:
16474494.
9. Warren JW, Keay SK. Interstitial cystitis. Curr Opin Urol 2002;12:69-74. PMID:
11753137.
10. Berry SH, Elliott MN, Suttorp M, Bogart LM, Stoto MA, Eggers P, et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol 2011;186:540-544. PMID:
21683389.
11. Moutzouris DA, Falagas ME. Interstitial cystitis: an unsolved enigma. Clin J Am Soc Nephrol 2009;4:1844-1857. PMID:
19808225.
12. Clemens JQ, Stoto MA, Elliott M, Suttorp M, Bogart L, Berry SH. Prevalence of interstitial cystitis/painful bladder syndrome in the United States [abstract]. Neurourol Urodyn 2009;28:907 Meeting abstract no. 261..
13. Johansson SL, Fall M. Clinical features and spectrum of light microscopic changes in interstitial cystitis. J Urol 1990;143:1118-1124. PMID:
2342171.
14. Ottem DP, Teichman JM. What is the value of cystoscopy with hydrodistension for interstitial cystitis? Urology 2005;66:494-499. PMID:
16140064.
15. Parsons CL, Greenberger M, Gabal L, Bidair M, Barme G. The role of urinary potassium in the pathogenesis and diagnosis of interstitial cystitis. J Urol 1998;159:1862-1866. PMID:
9598476.
16. Persu C, Cauni V, Gutue S, Blaj I, Jinga V, Geavlete P. From interstitial cystitis to chronic pelvic pain. J Med Life 2010;3:167-174. PMID:
20968203.
17. Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, Fitzgerald MP, et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol 2011;185:2162-2170. PMID:
21497847.
18. Hanno PM. Analysis of long-term Elmiron therapy for interstitial cystitis. Urology 1997;49(5A Suppl):93-99. PMID:
9146008.
19. Bouchelouche K, Nordling J. Recent developments in the management of interstitial cystitis. Curr Opin Urol 2003;13:309-313. PMID:
12811295.
20. Erickson DR, Xie SX, Bhavanandan VP, Wheeler MA, Hurst RE, Demers LM, et al. A comparison of multiple urine markers for interstitial cystitis. J Urol 2002;167:2461-2469. PMID:
11992058.
21. Keay S, Zhang CO, Hise MK, Hebel JR, Jacobs SC, Gordon D, et al. A diagnostic in vitro urine assay for interstitial cystitis. Urology 1998;52:974-978. PMID:
9836539.
22. Moldwin RM, Evans RJ, Stanford EJ, Rosenberg MT. Rational approaches to the treatment of patients with interstitial cystitis. Urology 2007;69(4 Suppl):73-81. PMID:
17462484.
23. Slobodov G, Feloney M, Gran C, Kyker KD, Hurst RE, Culkin DJ. Abnormal expression of molecular markers for bladder impermeability and differentiation in the urothelium of patients with interstitial cystitis. J Urol 2004;171:1554-1558. PMID:
15017219.
24. Keay SK, Szekely Z, Conrads TP, Veenstra TD, Barchi JJ Jr, Zhang CO, et al. An antiproliferative factor from interstitial cystitis patients is a frizzled 8 protein-related sialoglycopeptide. Proc Natl Acad Sci U S A 2004;101:11803-11808. PMID:
15282374.
25. Keay S, Zhang CO, Marvel R, Chai T. Antiproliferative factor, heparin-binding epidermal growth factor-like growth factor, and epidermal growth factor: sensitive and specific urine markers for interstitial cystitis. Urology 2001;57(6 Suppl 1):104. PMID:
11378066.
26. Kim JC, Park EY, Seo SI, Park YH, Hwang TK. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 2006;175:1773-1776. PMID:
16600756.
27. Liu HT, Tyagi P, Chancellor MB, Kuo HC. Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. BJU Int 2010;106:1681-1685. PMID:
19751258.
28. Nazif O, Teichman JM, Gebhart GF. Neural upregulation in interstitial cystitis. Urology 2007;69(4 Suppl):24-33. PMID:
17462476.
29. Chai TC, Keay S. New theories in interstitial cystitis. Nat Clin Pract Urol 2004;1:85-89. PMID:
16474520.
30. Kushner L, Chiu PY, Brettschneider N, Lipstein A, Eisenberg E, Rofeim O, et al. Urinary substance P concentration correlates with urinary frequency and urgency in interstitial cystitis patients treated with intravesical dimethyl sulfoxide and not intravesical anesthetic cocktail. Urology 2001;57(6 Suppl 1):129. PMID:
11378126.
31. Sanchez Freire V, Burkhard FC, Kessler TM, Kuhn A, Draeger A, Monastyrskaya K. MicroRNAs may mediate the down-regulation of neurokinin-1 receptor in chronic bladder pain syndrome. Am J Pathol 2010;176:288-303. PMID:
20008142.
32. Birder LA, Wolf-Johnston A, Buffington CA, Roppolo JR, de Groat WC, Kanai AJ. Altered inducible nitric oxide synthase expression and nitric oxide production in the bladder of cats with feline interstitial cystitis. J Urol 2005;173:625-629. PMID:
15643277.
33. Jacobs BL, Smaldone MC, Tyagi V, Philips BJ, Jackman SV, Leng WW, et al. Increased nerve growth factor in neurogenic overactive bladder and interstitial cystitis patients. Can J Urol 2010;17:4989-4994. PMID:
20156378.
34. Keay S, Zhang CO, Kagen DI, Hise MK, Jacobs SC, Hebel JR, et al. Concentrations of specific epithelial growth factors in the urine of interstitial cystitis patients and controls. J Urol 1997;158:1983-1988. PMID:
9334654.
35. Ongusaha PP, Kwak JC, Zwible AJ, Macip S, Higashiyama S, Taniguchi N, et al. HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res 2004;64:5283-5290. PMID:
15289334.
36. Freeman MR, Yoo JJ, Raab G, Soker S, Adam RM, Schneck FX, et al. Heparin-binding EGF-like growth factor is an autocrine growth factor for human urothelial cells and is synthesized by epithelial and smooth muscle cells in the human bladder. J Clin Invest 1997;99:1028-1036. PMID:
9062361.
37. Schneider MR, Wolf E. The epidermal growth factor receptor ligands at a glance. J Cell Physiol 2009;218:460-466. PMID:
19006176.
38. Kim J, Adam RM, Freeman MR. Trafficking of nuclear heparin-binding epidermal growth factor-like growth factor into an epidermal growth factor receptor-dependent autocrine loop in response to oxidative stress. Cancer Res 2005;65:8242-8249. PMID:
16166300.
39. Keay S. Cell signaling in interstitial cystitis/painful bladder syndrome. Cell Signal 2008;20:2174-2179. PMID:
18602988.
40. Keay S, Zhang CO, Shoenfelt JL, Chai TC. Decreased in vitro proliferation of bladder epithelial cells from patients with interstitial cystitis. Urology 2003;61:1278-1284. PMID:
12809929.
41. Keay S, Kleinberg M, Zhang CO, Hise MK, Warren JW. Bladder epithelial cells from patients with interstitial cystitis produce an inhibitor of heparin-binding epidermal growth factor-like growth factor production. J Urol 2000;164:2112-2118. PMID:
11061938.
42. Shahjee HM, Koch KR, Guo L, Zhang CO, Keay SK. Antiproliferative factor decreases Akt phosphorylation and alters gene expression via CKAP4 in T24 bladder carcinoma cells. J Exp Clin Cancer Res 2010;29:160. PMID:
21143984.
43. Keay S, Kaczmarek P, Zhang CO, Koch K, Szekely Z, Barchi JJ Jr, et al. Normalization of proliferation and tight junction formation in bladder epithelial cells from patients with interstitial cystitis/painful bladder syndrome by d-proline and d-pipecolic acid derivatives of antiproliferative factor. Chem Biol Drug Des 2011;77:421-430. PMID:
21352500.
44. Keay S, Zhang CO, Trifillis AL, Hise MK, Hebel JR, Jacobs SC, et al. Decreased 3H-thymidine incorporation by human bladder epithelial cells following exposure to urine from interstitial cystitis patients. J Urol 1996;156:2073-2078. PMID:
8911393.
45. Keay S, Seillier-Moiseiwitsch F, Zhang CO, Chai TC, Zhang J. Changes in human bladder epithelial cell gene expression associated with interstitial cystitis or antiproliferative factor treatment. Physiol Genomics 2003;14:107-115. PMID:
12847144.
46. Lee T. New insights into the mechanism of the down-regulation of mast cells in the treatment of interstitial cystitis: possible role of siglecs. Int Neurourol J 2011;15:59-60. PMID:
21811693.
47. Rudick CN, Bryce PJ, Guichelaar LA, Berry RE, Klumpp DJ. Mast cell-derived histamine mediates cystitis pain. PLoS One 2008;3:e2096. PMID:
18461160.
48. Shie JH, Kuo HC. Higher levels of cell apoptosis and abnormal E-cadherin expression in the urothelium are associated with inflammation in patients with interstitial cystitis/painful bladder syndrome. BJU Int 2011;108(2 Pt 2):E136-E141. PMID:
21166752.
49. Planey SL, Keay SK, Zhang CO, Zacharias DA. Palmitoylation of cytoskeleton associated protein 4 by DHHC2 regulates antiproliferative factor-mediated signaling. Mol Biol Cell 2009;20:1454-1463. PMID:
19144824.
50. Conrads TP, Tocci GM, Hood BL, Zhang CO, Guo L, Koch KR, et al. CKAP4/p63 is a receptor for the frizzled-8 protein-related antiproliferative factor from interstitial cystitis patients. J Biol Chem 2006;281:37836-37843. PMID:
17030514.
51. Kim J, Keay SK, Freeman MR. Heparin-binding epidermal growth factor-like growth factor functionally antagonizes interstitial cystitis antiproliferative factor via mitogen-activated protein kinase pathway activation. BJU Int 2009;103:541-546. PMID:
18990151.
52. Kim J, Keay SK, Dimitrakov JD, Freeman MR. p53 mediates interstitial cystitis antiproliferative factor (APF)-induced growth inhibition of human urothelial cells. FEBS Lett 2007;581:3795-3799. PMID:
17628545.
54. Zhang J, Planey SL, Ceballos C, Stevens SM Jr, Keay SK, Zacharias DA. Identification of CKAP4/p63 as a major substrate of the palmitoyl acyltransferase DHHC2, a putative tumor suppressor, using a novel proteomics method. Mol Cell Proteomics 2008;7:1378-1388. PMID:
18296695.
55. Resh MD. Palmitoylation of ligands, receptors, and intracellular signaling molecules. Sci STKE 2006;2006:re14. PMID:
17077383.
56. Zhang CO, Wang JY, Koch KR, Keay S. Regulation of tight junction proteins and bladder epithelial paracellular permeability by an antiproliferative factor from patients with interstitial cystitis. J Urol 2005;174:2382-2387. PMID:
16280852.
57. Kim J, Adam RM, Freeman MR. Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation. Cancer Res 2002;62:1549-1554. PMID:
11888934.
58. Swiatkowski S, Seifert HH, Steinhoff C, Prior A, Thievessen I, Schliess F, et al. Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. Exp Cell Res 2003;282:48-57. PMID:
12490193.
59. Li Z, Zhu Y, Yu M, Ji D, Yang Z, Kong C. c-Jun is involved in interstitial cystitis antiproliferative factor (APF)-induced growth inhibition of human bladder cancer T24 cells. Urol Oncol 2011 8 25;[Epub]. DOI:
10.1016/j.urolonc.2010.11.011.
60. Ching CB, Hansel DE. Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway. Lab Invest 2010;90:1406-1414. PMID:
20661228.
61. Hers I, Vincent EE, Tavaré JM. Akt signalling in health and disease. Cell Signal 2011;23:1515-1527. PMID:
21620960.
62. Dillon RL, Muller WJ. Distinct biological roles for the akt family in mammary tumor progression. Cancer Res 2010;70:4260-4264. PMID:
20424120.
63. Gonzalez E, McGraw TE. The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle 2009;8:2502-2508. PMID:
19597332.
64. Bozulic L, Hemmings BA. PIKKing on PKB: regulation of PKB activity by phosphorylation. Curr Opin Cell Biol 2009;21:256-261. PMID:
19303758.
65. Bozulic L, Hemmings BA. PIKKing on PKB: regulation of PKB activity by phosphorylation. Curr Opin Cell Biol 2009;21:256-261. PMID:
19303758.
66. Knowles MA, Platt FM, Ross RL, Hurst CD. Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev 2009;28:305-316. PMID:
20013032.
67. Adam RM, Roth JA, Cheng HL, Rice DC, Khoury J, Bauer SB, et al. Signaling through PI3K/Akt mediates stretch and PDGF-BB-dependent DNA synthesis in bladder smooth muscle cells. J Urol 2003;169:2388-2393. PMID:
12771803.
68. Braithwaite AW, Del Sal G, Lu X. Some p53-binding proteins that can function as arbiters of life and death. Cell Death Differ 2006;13:984-993. PMID:
16575404.
69. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998;282:1497-1501. PMID:
9822382.
70. Chène P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 2003;3:102-109. PMID:
12563309.
71. Sun Y. p53 and its downstream proteins as molecular targets of cancer. Mol Carcinog 2006;45:409-415. PMID:
16652354.
72. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006;6:909-923. PMID:
17128209.
73. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005;24:2899-2908. PMID:
15838523.
74. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-299. PMID:
9153395.
75. Cooper MJ, Haluschak JJ, Johnson D, Schwartz S, Morrison LJ, Lippa M, et al. p53 mutations in bladder carcinoma cell lines. Oncol Res 1994;6:569-579. PMID:
7787250.
76. Lane DP. Exploiting the p53 pathway for the diagnosis and therapy of human cancer. Cold Spring Harb Symp Quant Biol 2005;70:489-497. PMID:
16869788.
77. Chen L, Gilkes DM, Pan Y, Lane WS, Chen J. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J 2005;24:3411-3422. PMID:
16163388.
78. Cummins JM, Vogelstein B. HAUSP is required for p53 destabilization. Cell Cycle 2004;3:689-692. PMID:
15118411.
79. Khanna KK, Keating KE, Kozlov S, Scott S, Gatei M, Hobson K, et al. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet 1998;20:398-400. PMID:
9843217.
80. Moumen A, Masterson P, O'Connor MJ, Jackson SP. hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage. Cell 2005;123:1065-1078. PMID:
16360036.
81. Meek DW, Hupp TR. The regulation of MDM2 by multisite phosphorylation-opportunities for molecular-based intervention to target tumours? Semin Cancer Biol 2010;20:19-28. PMID:
19897041.
82. MacLaine NJ, Hupp TR. How phosphorylation controls p53. Cell Cycle 2011;10:916-921. PMID:
21350334.
84. Chai TC, Zhang CO, Shoenfelt JL, Johnson HW Jr, Warren JW, Keay S. Bladder stretch alters urinary heparin-binding epidermal growth factor and antiproliferative factor in patients with interstitial cystitis. J Urol 2000;163:1440-1444. PMID:
10751853.